Inflammation, adiponectin, obesity and cardiovascular risk

Current Medicinal Chemistry

Volumn 17, Issue 36, 2010, Pages 4511-4520

  Mangge, H ^a   Almer, G ^a   Truschnig Wilders, M ^a   Schmidt, A ^b   Gasser, R ^b   Fuchs, D ^c  

^a Centre of Medical Research (ZMF)   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adiposity; Cardiovascular risk; Immune mediated inflammation

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CD11B ANTIGEN; CD18 ANTIGEN; CD31 ANTIGEN; CELL ADHESION MOLECULE; ENDOCANNABINOID; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MICRORNA; NEOPTERIN; SELECTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MONOCYTE; NONHUMAN; OBESITY; SMOOTH MUSCLE FIBER; TH1 CELL; TH2 CELL;

ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; OBESITY; RISK FACTORS;

EID: 78650663578     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710794183006     Document Type: Article

References (134)

1. Zimmet, P.; Alberti, K. G.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature, 2001, 414(6865), 782-787.
2. Califf, R. M. Key issues for global cardiovascular medicine. Lancet, 2009, 374(9689), 508-510.
3. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-126.
4. Libby, P.; Ridker, P. M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105(9), 1135-114.
5. Libby, P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr. Rev., 2007, 65 (12 Pt 2), S140-146.
6. Stary, H. C.; Chandler, A. B.; Glagov, S.; Guyton, J. R.; Insull, W. Jr.; Rosenfeld, M. E.; Schaffer, S. A.; Schwartz, C. J.; Wagner, W. D.; Wissler, R. W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1994, 89(5), 2462-2478.
7. Napoli, C.; D'Armiento, F. P.; Mancini, F. P.; Postiglione, A.; Witztum, J. L.; Palumbo, G.; Palinski, W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest., 1997, 100(11), 2680-2690.
8. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352(16), 1685-1695.
9. Zernecke, A.; Shagdarsuren, E.; Weber, C. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol., 2008, 28(11), 1897-1908.
10. Weber, C.; Zernecke, A.; Libby, P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol., 2008, 8(10), 802-815.
11. Giannini, C.; de Giorgis, T.; Scarinci, A.; Cataldo, I.; Marcovecchio, M. L.; Chiarelli, F.; Mohn, A. Increased carotid intima-media thickness in pre-pubertal children with constitutional leanness and severe obesity: the speculative role of insulin sensitivity, oxidant status, and chronic inflammation. Eur. J. Endocrinol., 2009, 161(1), 73-80.
12. Cuomo, S.; Guarini, P.; Gaeta, G.; De Michele, M.; Boeri, F.; Dorn, J.; Bond, M.; Trevisan, M. Increased carotid intima-media thickness in children-adolescents, and young adults with a parental history of premature myocardial infarction. Eur. Heart J., 2002, 23(17), 1345-1350.
13. Mangge, H.; Schauenstein, K.; Stroedter, L.; Griesl, A.; Maerz, W.; Borkenstein, M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp. Clin. Endocrinol. Diabetes, 2004, 112(7), 378-382.
14. Glagov, S.; Weisenberg, E.; Zarins, C. K.; Stankunavicius, R.; Kolettis, G. J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med., 1987, 316(22), 1371-1375.
15. Rogacev, K. S.; Ulrich, C.; Blomer, L.; Hornof, F.; Oster, K.; Ziegelin, M.; Cremers, B.; Grenner, Y.; Geisel, J.; Schlitt, A.; Kohler, H.; Fliser, D.; Girndt, M.; Heine, G. H. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur. Heart J, 2009, 31(3), 369-376.
16. de Boer, O. J.; Becker, A. E.; van der Wal, A. C. T lymphocytes in atherogenesis-functional aspects and antigenic repertoire. Cardiovasc. Res., 2003, 60(1), 78-86.
17. Gautier, E. L.; Huby, T.; Witztum, J. L.; Ouzilleau, B.; Miller, E. R.; Saint-Charles, F.; Aucouturier, P.; Chapman, M. J.; Lesnik, P. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation, 2009, 119(13), 1795-1804.
18. Lutgens, E.; Gijbels, M.; Smook, M.; Heeringa, P.; Gotwals, P.; Koteliansky, V. E.; Daemen, M. J. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol., 2002, 22(6), 975-982.
19. Brisset, A. C.; Isakson, B. E.; Kwak, B. R. Connexins in vascular physiology and pathology. Antioxid. Redox Signal, 2009, 11(2), 267-282.
20. Jialal, I.; Devaraj, S. Jupiter to Earth: CRP Promotes Atherothrombosis. Metab. Syndr. Relat. Disord., 2009, 7(1), 1-3.
21. Devaraj, S.; Yun, J. M.; Duncan-Staley, C.; Jialal, I. C-reactive protein induces M-CSF release and macrophage proliferation. J. Leukoc. Biol., 2009, 85(2), 262-267.
22. Sugiyama, S.; Okada, Y.; Sukhova, G. K.; Virmani, R.; Heinecke, J. W.; Libby, P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol., 2001, 158(3), 879-891.
23. Cybulsky, M. I.; Hegele, R. A. The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J. Clin. Invest., 2003, 111(8), 1118-1120.
24. von Hundelshausen, P.; Weber, K. S.; Huo, Y.; Proudfoot, A. E.; Nelson, P. J.; Ley, K.; Weber, C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation, 2001, 103(13), 1772-1777.
25. Duan, S. Z.; Usher, M. G.; Mortensen, R. M. PPARs: the vasculature, inflammation and hypertension. Curr. Opin Nephrol. Hypertens., 2009, 18(2), 128-133.
26. Grammer, T. B.; Fuchs, D.; Boehm, B. O.; Winkelmann, B. R.; Maerz, W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin. Chem., 2009, 55(6), 1135-1146.
27. Avanzas, P.; Arroyo-Espliguero, R.; Quiles, J.; Roy, D.; Kaski, J. C. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur. Heart J., 2005, 26(5), 457-463.
28. Fuchs, D.; Avanzas, P.; Arroyo-Espliguero, R.; Jenny, M.; Consuegra-Sanchez, L.; Kaski, J. C. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr. Med. Chem., 2009, 16(35), 4644-4653.
29. Hansson, G. K.; Jonasson, L.; Seifert, P. S.; Stemme, S. Immune mechanisms in atherosclerosis. Arteriosclerosis, 1989, 9(5), 567-578.
30. Eid, R. E.; Rao, D. A.; Zhou, J.; Lo, S. F.; Ranjbaran, H.; Gallo, A.; Sokol, S. I.; Pfau, S.; Pober, J. S.; Tellides, G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation, 2009, 119(10), 1424-1432.
31. Mallat, Z.; Henry, P.; Fressonnet, R.; Alouani, S.; Scoazec, A.; Beaufils, P.; Chvatchko, Y.; Tedgui, A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart, 2002, 88(5), 467-469.
32. Blankenberg, S.; Tiret, L.; Bickel, C.; Peetz, D.; Cambien, F.; Meyer, J.; Rupprecht, H. J. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation, 2002, 106(1), 24-30.
33. Yamashita, H.; Shimada, K.; Seki, E.; Mokuno, H.; Daida, H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am. J. Cardiol., 2003, 91(2), 133-136.
34. Stemme, S.; Faber, B.; Holm, J.; Wiklund, O.; Witztum, J. L.; Hansson, G. K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A., 1995, 92(9), 3893-3897.
35. Folcik, V. A.; Aamir, R.; Cathcart, M. K. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler. Thromb. Vasc. Biol., 1997, 17(10), 1954-1961.
36. Cattaruzza, M.; Slodowski, W.; Stojakovic, M.; Krzesz, R.; Hecker, M. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J. Biol. Chem., 2003, 278(39), 37874-37880.
37. Pinderski, L. J.; Fischbein, M. P.; Subbanagounder, G.; Fishbein, M. C.; Kubo, N.; Cheroutre, H.; Curtiss, L. K.; Berliner, J. A.; Boisvert, W. A. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res., 2002, 90(10), 1064-1071.
38. Packard, R. R.; Lichtman, A. H.; Libby, P. Innate and adaptive immunity in atherosclerosis. Semin. Immunopathol., 2009, 31(1), 5-22.
39. Nathan, C. F.; Murray, H. W.; Wiebe, M. E.; Rubin, B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med., 1983, 158(3), 670-689.
40. Schreck, R.; Rieber, P.; Baeuerle, P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J., 1991, 10(8), 2247-2258.
41. Muller, J. M.; Ziegler-Heitbrock, H. W.; Baeuerle, P. A. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology, 1993, 187 (3-5), 233-256.
42. Buckland, G.; Gonzalez, C. A.; Agudo, A.; Vilardell, M.; Berenguer, A.; Amiano, P.; Ardanaz, E.; Arriola, L.; Barricarte, A.; Basterretxea, M.; Chirlaque, M. D.; Cirera, L.; Dorronsoro, M.; Egues, N.; Huerta, J. M.; Larranaga, N.; Marin, P.; Martinez, C.; Molina, E.; Navarro, C.; Quiros, J. R.; Rodriguez, L.; Sanchez, M. J.; Tormo, M. J.; Moreno-Iribas, C. Adherence to the Mediterranean diet and risk of coronary heart disease in the Spanish EPIC Cohort Study. Am. J. Epidemiol., 2009, 170(12), 1518-1529.
43. Sesso, H. D.; Buring, J. E.; Christen, W. G.; Kurth, T.; Belanger, C.; MacFadyen, J.; Bubes, V.; Manson, J. E.; Glynn, R. J.; Gaziano, J. M. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA, 2008, 300(18), 2123-2133.
44. Brunner, E. J.; Rees, K.; Ward, K.; Burke, M.; Thorogood, M. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst. Rev., 2007(4), CD002128.
45. Ristow, M.; Zarse, K.; Oberbach, A.; Kloting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C. R.; Bluher, M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(21), 8665-8670.
46. Powers, S. K.; Jackson, M. J. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol. Rev., 2008, 88(4), 1243-1276.
47. Winkler, C.; Frick, B.; Schroecksnadel, K.; Schennach, H.; Fuchs, D. Food preservatives sodium sulfite and sorbic acid suppress mitogen-stimulated peripheral blood mononuclear cells. Food Chem. Toxicol., 2006, 44(12), 2003-2007.
48. Shen, X. H.; Tang, Q. Y.; Huang, J.; Cai, W. Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity. Exp. Biol. Med. (Maywood), 235(1), 47-51.
49. Chen, T.; Huang, Z.; Wang, L.; Wang, Y.; Wu, F.; Meng, S.; Wang, C. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc. Res., 2009, 83(1), 131-139.
50. Ishigaki, Y.; Oka, Y.; Katagiri, H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr. Opin. Lipidol., 2009 20(5), 363-369.
51. Rajavashisth, T. B.; Andalibi, A.; Territo, M. C.; Berliner, J. A.; Navab, M.; Fogelman, A. M.; Lusis, A. J. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature, 1990, 344(6263), 254-257.
52. Leonard, E. J.; Yoshimura, T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol. Today, 1990, 11(3), 97-101.
53. Soto, Y.; Conde, H.; Aroche, R.; Brito, V.; Luaces, P.; Nasiff, A.; Obregon, A.; Vazquez Lopez, A. M. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease. Hum. Antibodies, 2009, 18(3), 109-117.
54. Frostegard, J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun. Rev., 2002, 1(4), 233-237.
55. Freigang, S.; Horkko, S.; Miller, E.; Witztum, J. L.; Palinski, W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde- modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol., 1998, 18(12), 1972-1982.
56. Stopeck, A. T.; Nicholson, A. C.; Mancini, F. P.; Hajjar, D. P. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J. Biol. Chem., 1993, 268(23), 17489-17494.
57. Hajjar, D. P.; Haberland, M. E. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J. Biol. Chem., 1997, 272(37), 22975-22978.
58. Gierens, H.; Nauck, M.; Roth, M.; Schinker, R.; Schurmann, C.; Scharnagl, H.; Neuhaus, G.; Wieland, H.; Marz, W. Interleukin-6 stimulates LDL receptor gene expression via activation of sterolresponsive and Sp1 binding elements. Arterioscler. Thromb. Vasc. Biol., 2000, 20(7), 1777-1783.
59. Falcone, D. J.; McCaffrey, T. A.; Vergilio, J. A. Stimulation of macrophage urokinase expression by polyanions is protein kinase C-dependent and requires protein and RNA synthesis. J. Biol. Chem., 1991, 266(33), 22726-22732.
60. Geng, Y. J.; Libby, P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am. J. Pathol., 1995, 147(2), 251-266.
61. Okumura, T.; Fujioka, Y.; Morimoto, S.; Masai, M.; Sakoda, T.; Tsujino, T.; Kashiwamura, S.; Okamura, H.; Ohyanagi, M. Chylomicron remnants stimulate release of interleukin-1beta by THP-1 cells. J. Atheroscler. Thromb., 2006, 13(1), 38-45.
62. Braunersreuther, V.; Mach, F. Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches? Cell Mol. Life Sci., 2006, 63(18), 2079-2088.
63. Mach, F.; Montecucco, F.; Steffens, S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. B r. J. Pharmacol., 2008, 153(2), 290-298.
64. Hansson, G. K.; Libby, P.; Schonbeck, U.; Yan, Z. Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res., 2002, 91(4), 281-291.
65. Kershaw, E. E.; Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 2004, 89(6), 2548-2556.
66. Friedman, J. M. Obesity in the new millennium. Nature, 2000, 404(6778), 632-634.
67. Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun., 1996, 221(2), 286-289.
68. Scherer, P. E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 1995, 270(45), 26746-26749.
69. Chandran, M.; Phillips, S. A.; Ciaraldi, T.; Henry, R. R. Adiponectin: more than just another fat cell hormone? Diabetes Care, 2003, 26(8), 2442-2450.
70. Mangge, H.; Almer, G.; Haj-Yahya, S.; Grandits, N.; Gasser, R.; Pilz, S.; Moller, R.; Horejsi, R. Nuchal thickness of subcutaneous adipose tissue is tightly associated with an increased LMW/total adiponectin ratio in obese juveniles. Atherosclerosis, 2009, 203(1), 277-283.
71. Mangge, H.; Almer, G.; Haj-Yahya, S.; Pilz, S.; Gasser, R.; Moller, R.; Horejsi, R. Preatherosclerosis and adiponectin subfractions in obese adolescents. Obesity (Silver Spring), 2008, 16(12), 2578-2584.
72. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 1999, 257(1), 79-83.
73. Bobbert, T.; Rochlitz, H.; Wegewitz, U.; Akpulat, S.; Mai, K.; Weickert, M. O.; Mohlig, M.; Pfeiffer, A. F.; Spranger, J. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes, 2005, 54(9), 2712-2719.
74. Waki, H.; Yamauchi, T.; Kamon, J.; Kita, S.; Ito, Y.; Hada, Y.; Uchida, S.; Tsuchida, A.; Takekawa, S.; Kadowaki, T. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology, 2005, 146(2), 790-796.
75. Fruebis, J.; Tsao, T. S.; Javorschi, S.; Ebbets-Reed, D.; Erickson, M. R.; Yen, F. T.; Bihain, B. E.; Lodish, H. F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U S A, 2001, 98(4), 2005-2010.
76. Bruce, C. R.; Mertz, V. A.; Heigenhauser, G. J.; Dyck, D. J. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes, 2005, 54(11), 3154-3160.
77. Palanivel, R.; Fang, X.; Park, M.; Eguchi, M.; Pallan, S.; De Girolamo, S.; Liu, Y.; Wang, Y.; Xu, A.; Sweeney, G. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc. Res., 2007, 75(1), 148-157.
78. Sun, Y.; Xun, K.; Wang, C.; Zhao, H.; Bi, H.; Chen, X.; Wang, Y. Adiponectin, an unlocking adipocytokine. Cardiovasc. Ther., 2009, 27(1), 59-75.
79. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N. H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R.; Kadowaki, T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423(6941), 762-769.
80. Hug, C.; Wang, J.; Ahmad, N. S.; Bogan, J. S.; Tsao, T. S.; Lodish, H. F. T-cadherin is a receptor for hexameric and high-molecularweight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(28), 10308-10313.
81. Takemura, Y.; Ouchi, N.; Shibata, R.; Aprahamian, T.; Kirber, M. T.; Summer, R. S.; Kihara, S.; Walsh, K. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest., 2007, 117(2), 375-386.
82. Okamoto, Y.; Arita, Y.; Nishida, M.; Muraguchi, M.; Ouchi, N.; Takahashi, M.; Igura, T.; Inui, Y.; Kihara, S.; Nakamura, T.; Yamashita, S.; Miyagawa, J.; Funahashi, T.; Matsuzawa, Y. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm. Metab. Res., 2000, 32(2), 47-50.
83. Saito, K.; Tobe, T.; Minoshima, S.; Asakawa, S.; Sumiya, J.; Yoda, M.; Nakano, Y.; Shimizu, N.; Tomita, M. Organization of the gene for gelatin-binding protein (GBP28). Gene, 1999, 229 (1-2), 67-73.
84. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100(25), 2473-2476.
85. Yu, J. G.; Javorschi, S.; Hevener, A. L.; Kruszynska, Y. T.; Norman, R. A.; Sinha, M.; Olefsky, J. M. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes, 2002, 51(10), 2968-2974.
86. Szmitko, P. E.; Teoh, H.; Stewart, D. J.; Verma, S. Adiponectin and cardiovascular disease: state of the art? Am. J. Physiol. Heart Circ. Physiol., 2007, 292(4), H1655-1663.
87. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation, 2000, 102(11), 1296-1301.
88. Cai, X. J.; Li, C. J.; Chen, L.; Rong, Y. Y.; Zhang, Y.; Zhang, M. A hypothesis: adiponectin mediates anti-atherosclerosis via adventitia-AMPK-iNOS pathway. Med. Hypotheses, 2008, 70(5), 1044-1047.
89. Kamigaki, M.; Sakaue, S.; Tsujino, I.; Ohira, H.; Ikeda, D.; Itoh, N.; Ishimaru, S.; Ohtsuka, Y.; Nishimura, M. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 2006, 339(2), 624-632.
90. Fasshauer, M.; Klein, J.; Neumann, S.; Eszlinger, M.; Paschke, R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett., 2001, 507(2), 142-146.
91. Kim, K. Y.; Kim, J. K.; Jeon, J. H.; Yoon, S. R.; Choi, I.; Yang, Y. c-Jun. N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 2005, 327(2), 460-467.
92. Nishizawa, H.; Shimomura, I.; Kishida, K.; Maeda, N.; Kuriyama, H.; Nagaretani, H.; Matsuda, M.; Kondo, H.; Furuyama, N.; Kihara, S.; Nakamura, T.; Tochino, Y.; Funahashi, T.; Matsuzawa, Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 2002, 51(9), 2734-2741.
93. Gable, D. R.; Hurel, S. J.; Humphries, S. E. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis, 2006, 188(2), 231-244.
94. Mantzoros, C. S.; Williams, C. J.; Manson, J. E.; Meigs, J. B.; Hu, F. B. Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am. J. Clin. Nutr., 2006, 84(2), 328-335.
95. Tsukinoki, R.; Morimoto, K.; Nakayama, K. Association between lifestyle factors and plasma adiponectin levels in Japanese men. Lipids Health Dis., 2005, 4, 27.
96. Fragopoulou, E.; Panagiotakos, D. B.; Pitsavos, C.; Tampourlou, M.; Chrysohoou, C.; Nomikos, T.; Antonopoulou, S.; Stefanadis, C. The association between adherence to the Mediterranean diet and adiponectin levels among healthy adults: the ATTICA study. J. Nutr. Biochem., 2010, 21(4), 285-289.
97. Miyazaki, S.; Izawa, T.; Ogasawara, J. E.; Sakurai, T.; Nomura, S.; Kizaki, T.; Ohno, H.; Komabayashi, T. Effect of exercise training on adipocyte-size-dependent expression of leptin and adiponectin. Life Sci., 2010, 86 (17-18), 691-698.
98. Weyer, C.; Salbe, A. D.; Lindsay, R. S.; Pratley, R. E.; Bogardus, C.; Tataranni, P. A. Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism, 2001, 50(2), 223-230.
99. Kazumi, T.; Kawaguchi, A.; Hirano, T.; Yoshino, G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism, 2004, 53(5), 589-593.
100. Iwashima, Y.; Katsuya, T.; Ishikawa, K.; Ouchi, N.; Ohishi, M.; Sugimoto, K.; Fu, Y.; Motone, M.; Yamamoto, K.; Matsuo, A.; Ohashi, K.; Kihara, S.; Funahashi, T.; Rakugi, H.; Matsuzawa, Y.; Ogihara, T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension, 2004, 43(6), 1318-1323.
101. Hosogai, N.; Fukuhara, A.; Oshima, K.; Miyata, Y.; Tanaka, S.; Segawa, K.; Furukawa, S.; Tochino, Y.; Komuro, R.; Matsuda, M.; Shimomura, I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes, 2007, 56(4), 901-911.
102. Madsen, E. L.; Rissanen, A.; Bruun, J. M.; Skogstrand, K.; Tonstad, S.; Hougaard, D. M.; Richelsen, B. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur. J. Endocrinol., 2008, 158(2), 179-187.
103. Fasshauer, M.; Klein, J.; Neumann, S.; Eszlinger, M.; Paschke, R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 2002, 290(3), 1084-1089.
104. Imagawa, A.; Funahashi, T.; Nakamura, T.; Moriwaki, M.; Tanaka, S.; Nishizawa, H.; Sayama, K.; Uno, S.; Iwahashi, H.; Yamagata, K.; Miyagawa, J.; Matsuzawa, Y. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care, 2002, 25(9), 1665-1666.
105. Semple, R. K.; Soos, M. A.; Luan, J.; Mitchell, C. S.; Wilson, J. C.; Gurnell, M.; Cochran, E. K.; Gorden, P.; Chatterjee, V. K.; Wareham, N. J.; O'Rahilly, S. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J. Clin. Endocrinol. Metab., 2006, 91(8), 3219-3223.
106. Halleux, C. M.; Takahashi, M.; Delporte, M. L.; Detry, R.; Funahashi, T.; Matsuzawa, Y.; Brichard, S. M. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem. Biophys. Res. Commun., 2001, 288(5), 1102-1107.
107. Karastergiou, K.; Evans, I.; Ogston, N.; Miheisi, N.; Nair, D.; Kaski, J. C.; Jahangiri, M.; Mohamed-Ali, V. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2010, 30(7), 1340-1346.
108. Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.; Kondo, H.; Takahashi, M.; Arita, Y.; Komuro, R.; Ouchi, N.; Kihara, S.; Tochino, Y.; Okutomi, K.; Horie, M.; Takeda, S.; Aoyama, T.; Funahashi, T.; Matsuzawa, Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med., 2002, 8(7), 731-737.
109. Kim, K. Y.; Kim, J. K.; Han, S. H.; Lim, J. S.; Kim, K. I.; Cho, D. H.; Lee, M. S.; Lee, J. H.; Yoon, D. Y.; Yoon, S. R.; Chung, J. W.; Choi, I.; Kim, E.; Yang, Y. Adiponectin is a negative regulator of NK cell cytotoxicity. J. Immunol., 2006, 176(10), 5958-5964.
110. Hattori, Y.; Hattori, S.; Akimoto, K.; Nishikimi, T.; Suzuki, K.; Matsuoka, H.; Kasai, K. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes, 2007, 56(3), 804-808.
111. Herder, C.; Hauner, H.; Haastert, B.; Rohrig, K.; Koenig, W.; Kolb, H.; Muller-Scholze, S.; Thorand, B.; Holle, R.; Rathmann, W. Hypoadiponectinemia and proinflammatory state: two sides of the same coin? results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabetes Care, 2006, 29(7), 1626-1631.
112. Chen, H.; Montagnani, M.; Funahashi, T.; Shimomura, I.; Quon, M. J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 2003, 278(45), 45021-45026.
113. Eid, H. M.; Lyberg, T.; Arnesen, H.; Seljeflot, I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis, 2007, 194(2), e1-8.
114. Motoshima, H.; Wu, X.; Mahadev, K.; Goldstein, B. J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun., 2004, 315(2), 264-271.
115. Kobayashi, H.; Ouchi, N.; Kihara, S.; Walsh, K.; Kumada, M.; Abe, Y.; Funahashi, T.; Matsuzawa, Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res., 2004, 94(4), e27-31.
116. Yang, H.; Zhang, R.; Mu, H.; Li, M.; Yao, Q.; Chen, C. Adiponectin promotes endothelial cell differentiation from human peripheral CD14+ monocytes in vitro. J. Cell. Mol. Med., 2006, 10(2), 459-469.
117. Gruber, H. J.; Mayer, C.; Mangge, H.; Fauler, G.; Grandits, N.; Wilders-Truschnig, M. Obesity reduces the bioavailability of nitric oxide in juveniles. Int. J. Obes. (Lond.), 2008, 32(5), 826-831.
118. Gruber, H. J.; Mayer, C.; Meinitzer, A.; Almer, G.; Horejsi, R.; Moller, R.; Pilz, S.; Marz, W.; Gasser, R.; Truschnig-Wilders, M.; Mangge, H. Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp. Clin. Endocrinol. Diabetes, 2008, 116(9), 520-524.
119. Kumada, M.; Kihara, S.; Sumitsuji, S.; Kawamoto, T.; Matsumoto, S.; Ouchi, N.; Arita, Y.; Okamoto, Y.; Shimomura, I.; Hiraoka, H.; Nakamura, T.; Funahashi, T.; Matsuzawa, Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol., 2003, 23(1), 85-89.
120. Arita, Y.; Kihara, S.; Ouchi, N.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Kumada, M.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Shimomura, I.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105(24), 2893-2898.
121. Wang, Y.; Lam, K. S.; Xu, J. Y.; Lu, G.; Xu, L. Y.; Cooper, G. J.; Xu, A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem., 2005, 280(18), 18341-18347.
122. Matsuzawa, Y.; Funahashi, T.; Kihara, S.; Shimomura, I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2004, 24(1), 29-33.
123. Ma, K.; Cabrero, A.; Saha, P. K.; Kojima, H.; Li, L.; Chang, B. H.; Paul, A.; Chan, L. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J. Biol. Chem., 2002, 277(38), 34658-34661.
124. Wolf, A. M.; Wolf, D.; Rumpold, H.; Enrich, B.; Tilg, H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun., 2004, 323(2), 630-635.
125. Tsatsanis, C.; Zacharioudaki, V.; Androulidaki, A.; Dermitzaki, E.; Charalampopoulos, I.; Minas, V.; Gravanis, A.; Margioris, A. N. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem. Biophys. Res. Commun., 2005, 335(4), 1254-1263.
126. Kubota, N.; Terauchi, Y.; Yamauchi, T.; Kubota, T.; Moroi, M.; Matsui, J.; Eto, K.; Yamashita, T.; Kamon, J.; Satoh, H.; Yano, W.; Froguel, P.; Nagai, R.; Kimura, S.; Kadowaki, T.; Noda, T. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem., 2002, 277(29), 25863-25866.
127. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K.; Sakai, N.; Shimomura, I.; Kobayashi, H.; Terasaka, N.; Inaba, T.; Funahashi, T.; Matsuzawa, Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2002, 106(22), 2767-2770.
128. Nawrocki, A. R.; Hofmann, S. M.; Teupser, D.; Basford, J. E.; Durand, J. L.; Jelicks, L. A.; Woo, C. W.; Kuriakose, G.; Factor, S. M.; Tanowitz, H. B.; Hui, D. Y.; Tabas, I.; Scherer, P. E. Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol., 30(6), 1159-1165.
129. Iglseder, B.; Mackevics, V.; Stadlmayer, A.; Tasch, G.; Ladurner, G.; Paulweber, B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke, 2005, 36(12), 2577-2582.
130. Pilz, S.; Horejsi, R.; Moller, R.; Almer, G.; Scharnagl, H.; Stojakovic, T.; Dimitrova, R.; Weihrauch, G.; Borkenstein, M.; Maerz, W.; Schauenstein, K.; Mangge, H. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J. Clin. Endocrinol. Metab., 2005, 90(8), 4792-4796.
131. Preis, S. R.; Massaro, J. M.; Hoffmann, U.; D'Agostino, R. B. Sr.; Levy, D.; Robins, S. J.; Meigs, J. B.; Vasan, R. S.; O'Donnell, C. J.; Fox, C. S. Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J. Clin. Endocrinol. Metab., 2010, 95(8), 3701-3710.
132. Laughlin, G. A.; Barrett-Connor, E.; May, S.; Langenberg, C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am. J. Epidemiol., 2007, 165(2), 164-174.
133. Sattar, N.; Wannamethee, G.; Sarwar, N.; Tchernova, J.; Cherry, L.; Wallace, A. M.; Danesh, J.; Whincup, P. H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006, 114(7), 623-629.
134. Fantuzzi, G. Adiponectin and inflammation: consensus and controversy. J. Allergy Clin. Immunol., 2008, 121(2), 326-330.